Imaging mass spectrometry: A new tool for pathology in a molecular age

Mass spectrometry (MS) provides unique advantages for the analysis of clinical specimens, and these capabilities have been critical to the advancement of diagnostic medicine. To date, LC‐MS is the MS platform most commonly used for diagnostics; however, LC‐MS based proteomics is very labor intensive and costly to implement for high volume assays. Furthermore, when analyzing tissue samples, additional laborious sample preparation steps must be employed (e.g. extraction methods or laser microdissection). The direct analysis of cells and tissues by MALDI imaging MS has developed significant momentum for applications that have diagnostic potential. MALDI imaging MS provides molecular information from specific cell types within tissue sections; however, this laser‐based approach significantly reduces the analysis time for each location sampled. This Viewpoint discusses the technologies for direct analysis of tissues, the potential for diagnostic applications using MALDI imaging MS, and the challenges faced in the transfer of the technology to the clinical laboratory.

[1]  M. Smith,et al.  Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma , 2011 .

[2]  Mahlon D. Johnson,et al.  Protein Profiling in Brain Tumors Using Mass Spectrometry , 2004, Clinical Cancer Research.

[3]  F. Mégraud,et al.  Matrix-assisted laser-desorption/ionization biotyper: experience in the routine of a University hospital. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  R. Caprioli,et al.  Matrix precoated targets for direct lipid analysis and imaging of tissue. , 2013, Analytical chemistry.

[5]  Detlev Suckau,et al.  Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. , 2010, Journal of proteome research.

[6]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[7]  R. Caprioli,et al.  Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. , 1997, Analytical chemistry.

[8]  H. R. Bergen,et al.  Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. , 2009, Blood.

[9]  L. Hall,et al.  Performance and Cost Analysis of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Routine Identification of Yeast , 2011, Journal of Clinical Microbiology.

[10]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[11]  Baogang J. Xu,et al.  Direct analysis of laser capture microdissected cells by MALDI mass spectrometry , 2002, Journal of the American Society for Mass Spectrometry.

[12]  Mariaelena Pierobon,et al.  Laser capture microdissection technology , 2007, Expert review of molecular diagnostics.

[13]  R. Montironi,et al.  Laser-assisted Microdissection in Translational Research: Theory, Technical Considerations, and Future Applications , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  Monica Morrow,et al.  Changes in breast cancer therapy because of pathology second opinions , 2002, Annals of Surgical Oncology.

[15]  Brian L Hood,et al.  Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue*S , 2005, Molecular & Cellular Proteomics.

[16]  T. Veenstra,et al.  Mass spectrometric analysis of formalin‐fixed paraffin‐embedded tissue: Unlocking the proteome within , 2006, Proteomics.

[17]  Erika Check,et al.  Proteomics and cancer: Running before we can walk? , 2004, Nature.

[18]  M. Stoeckli,et al.  Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues , 2001, Nature Medicine.

[19]  Richard M Caprioli,et al.  Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. , 2013, Chemical reviews.

[20]  Andreas Kowarsch,et al.  Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. , 2010, Journal of proteome research.

[21]  S. Nasr,et al.  How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. , 2012, Blood.

[22]  Preface to Genomic Pathology – a New Frontier , 2001, The Journal of pathology.

[23]  Kerri J Grove,et al.  Matrix Pre-Coated MALDI MS Targets for Small Molecule Imaging in Tissues , 2011, Journal of the American Society for Mass Spectrometry.

[24]  G. Chejfec.  Robbins Pathologic Basis of Disease , 2009 .

[25]  Richard M Caprioli,et al.  Imaging Mass Spectrometry—A New and Promising Method to Differentiate Spitz Nevi From Spitzoid Malignant Melanomas , 2012, The American Journal of dermatopathology.

[26]  D. Ransohoff.  Lessons from controversy: ovarian cancer screening and serum proteomics. , 2005, Journal of the National Cancer Institute.

[27]  P. Chaurand,et al.  Assessing protein patterns in disease using imaging mass spectrometry. , 2004, Journal of proteome research.

[28]  Arthur T. Johnson,et al.  Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring , 2012, Diagnostic Pathology.